These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32076874)

  • 1. Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
    Fujieda Y; Doi M; Asaka T; Ota M; Hisada R; Ohnishi N; Kono M; Kameda H; Nakazawa D; Kato M; Amengual O; Takahata M; Yasuda S; Kitagawa Y; Atsumi T
    J Bone Miner Metab; 2020 Jul; 38(4):581-588. PubMed ID: 32076874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
    Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
    J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.
    Fujieda Y; Atsumi T
    J Bone Miner Metab; 2020 Sep; 38(5):739-741. PubMed ID: 32591907
    [No Abstract]   [Full Text] [Related]  

  • 6. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
    Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
    Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
    Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
    PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
    Nashi M; Hirai T; Iwamoto T; Takenobu T
    J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.
    Hasegawa T; Ueda N; Yamada SI; Kato S; Iwata E; Hayashida S; Kojima Y; Shinohara M; Tojo I; Nakahara H; Yamaguchi T; Kirita T; Kurita H; Shibuya Y; Soutome S; Akashi M;
    Osteoporos Int; 2021 Nov; 32(11):2323-2333. PubMed ID: 33997909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
    Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
    Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
    Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan.
    Kunihara T; Tohmori H; Tsukamoto M; Kobayashi M; Okumura T; Teramoto H; Hamasaki T; Yamasaki T; Nakagawa T; Okimoto N; Fujiwara S
    Osteoporos Int; 2023 Jun; 34(6):1101-1109. PubMed ID: 37002373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incidence of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Urologic Cancers].
    Kawanishi H; Yokozeki H; Hoshiyama A; Watanabe H; Funahashi Y; Fujiwara M; Takashima Y; Shintani M; Yui S; Okumura K
    Hinyokika Kiyo; 2022 Jan; 68(1):1-6. PubMed ID: 35114759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update MRONJ and perspectives of its treatment.
    Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
    J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.
    Hasegawa T; Hayashida S; Kondo E; Takeda Y; Miyamoto H; Kawaoka Y; Ueda N; Iwata E; Nakahara H; Kobayashi M; Soutome S; Yamada SI; Tojyo I; Kojima Y; Umeda M; Fujita S; Kurita H; Shibuya Y; Kirita T; Komori T;
    Osteoporos Int; 2019 Jan; 30(1):231-239. PubMed ID: 30406309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.
    Kanno C; Kojima M; Tezuka Y; Yaginuma S; Kanaya Y; Kaneko T
    Bone; 2023 Dec; 177():116892. PubMed ID: 37689127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.